Dootson G M, Keidan J, Harper P L
Department of Dermatology, Queen Elizabeth Hospital, King's Lynn, Norfolk, U.K.
Br J Dermatol. 1995 Jul;133(1):66-70. doi: 10.1111/j.1365-2133.1995.tb02494.x.
A patient with haemophilia A and acne was recently reported to have experienced increased bleeding during therapy with isotretinoin. The aim of the present study was to investigate the influence of isotretinoin upon fibrinolysis, and more specifically upon tissue plasminogen activator (tPA) and tissue plasminogen activator inhibitor (PAI) levels, in haemostatically normal individuals. Thirteen patients with severe acne received a 4-month course of isotretinoin at a dose of 1 mg/kg per day. In all cases, the acne responded to therapy, and the patients did not show any evidence of unexpected bleeding or bruising throughout the study. Although all investigations remained within the normal range, tPA measurements rose significantly (P < 0.001) after 3 months' therapy compared with pretreatment values. Retinoids have been shown to stimulate tPA production in vitro from human endothelial cells. Our results confirm that this can be demonstrated in vivo. Prior to therapy with isotretinoin, when all patients had inflammatory acne, PAI measurements were elevated in 12 of 13 individuals. The mean measurement of PAI decreased from 98.38 +/- 63.30 ng/ml prior to treatment, to 24.63 +/- 15.2 ng/ml (P < 0.01) in the eight patients who returned for blood tests 6 weeks after completing therapy. The decline in PAI levels appears to reflect the resolving cutaneous inflammation following treatment with isotretinoin, rather than a direct effect of isotretinoin on the synthesis or release of PAI. This study provides further evidence that tPA production is stimulated by isotretinoin, and that this, together with falling PAI levels, may accelerate fibrinolysis. There was no clinical evidence that haemostasis was impaired in these haematologically normal individuals.(ABSTRACT TRUNCATED AT 250 WORDS)
最近有报告称,一名患有甲型血友病和痤疮的患者在接受异维A酸治疗期间出血增多。本研究的目的是调查异维A酸对止血功能正常个体的纤维蛋白溶解的影响,更具体地说是对组织纤溶酶原激活物(tPA)和组织纤溶酶原激活物抑制剂(PAI)水平的影响。13名重度痤疮患者接受了为期4个月的异维A酸治疗,剂量为每日1毫克/千克。在所有病例中,痤疮对治疗有反应,并且在整个研究过程中患者未出现任何意外出血或瘀伤的迹象。尽管所有检查结果均在正常范围内,但与治疗前值相比,治疗3个月后tPA测量值显著升高(P<0.001)。类视黄醇已被证明在体外可刺激人内皮细胞产生tPA。我们的结果证实这在体内也可得到证明。在接受异维A酸治疗前,所有患者均患有炎性痤疮,13名个体中有12名的PAI测量值升高。完成治疗6周后返回进行血液检查的8名患者中,PAI的平均测量值从治疗前的98.38±63.30纳克/毫升降至24.63±15.2纳克/毫升(P<0.01)。PAI水平的下降似乎反映了异维A酸治疗后皮肤炎症的消退,而不是异维A酸对PAI合成或释放的直接影响。本研究提供了进一步的证据,证明异维A酸可刺激tPA的产生,并且这与PAI水平的下降一起可能会加速纤维蛋白溶解。没有临床证据表明这些血液学正常的个体的止血功能受损。(摘要截选至250字)